Instillido

Lidocaine Hydrochloride, the active ingredient in Instillido, is a local anesthetic presented as a sterile solution for urethral use. It provides reversible nerve block to relieve discomfort during diagnostic or therapeutic procedures involving the urethra, as well as during catheter insertion or removal.

GNH USA supplies Instillido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory compliance support.

Instillido, a lidocaine‑based local anesthetic, is used for urethral anesthesia to facilitate various urological procedures.

- Urethral diagnostic procedures: provides local anesthesia to reduce pain and discomfort during cystoscopy or imaging studies. - Therapeutic urethral interventions: enables painless catheter insertion, removal, or dilation during treatment. - Urethral examinations: offers temporary numbness to improve patient tolerance during routine examinations.

Instillido may cause local or systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Burning or stinging at the urethral site. - Transient numbness of the urethral mucosa. - Mild urinary urgency.

Serious or Rare Side Effects: - Allergic reactions such as rash, itching, or swelling. - Systemic toxicity with dizziness, tinnitus, or seizures. - Cardiac arrhythmias or severe hypotension.

When using Instillido, clinicians should observe several precautions to ensure patient safety and product integrity.

- Allergy assessment: confirm no known hypersensitivity to lidocaine or other amide‑type local anesthetics. - Pregnancy: avoid unless clearly needed, as safety data are limited. - Breastfeeding: use with caution; lidocaine may be excreted in milk. - Concomitant CNS depressants: monitor for enhanced systemic toxicity. - Renal or hepatic impairment: consider dose adjustment or increased observation. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Lidocaine can interact with other medicines, altering its effect or increasing toxicity risk.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may cause additive cardiotoxicity. - Amiodarone: increases plasma lidocaine concentrations. - Cimetidine: reduces hepatic metabolism, raising lidocaine levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardia. - Calcium channel blockers: potential additive cardiac effects. - Other local anesthetics: risk of cumulative toxicity.